<p>Adherex Technologies Inc.（納斯達克代碼：FENC - 獲取免費報告）董事 Rosty Raykov 於 2 月 2 日星期一出售了 10,349 股該公司的股票。股票以平均價格 7.76 美元出售，總交易額為 80,308.24 美元。交易後，該董事直接持有 98,477 股公司的股票，價值 764,181.52 美元。這代表其持股比例下降了 9.51%。該交易已在與美國證券交易委員會（SEC）的法律文件中披露，相關信息可通過 SEC 網站獲取。</p>
<p>獲取 <strong>Adherex Technologies</strong> 的提醒：</p>
<p>Rosty Raykov 最近還進行了以下交易：</p>
<ul>
<li>在 12 月 5 日星期五，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均價格 7.54 美元出售，總價值為 75,400.00 美元。</li>
<li>在 11 月 5 日星期三，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均價格 8.10 美元出售，總價值為 81,000.00 美元。</li>
</ul>
<h2>Adherex Technologies 股票上漲 3.2%</h2>
<p>在週一的午盤交易中，納斯達克 FENC 的股票上漲了 0.24 美元，達到了 7.83 美元。該股票的交易量為 134,027 股，較其平均交易量 116,975 股有所增加。該公司的市值為 2.675 億美元，市盈率為-34.04，貝塔值為 0.78。該公司 50 日簡單移動平均線為 7.66 美元，200 日簡單移動平均線為 8.28 美元。Adherex Technologies Inc.的 12 個月低點為 4.68 美元，12 個月高點為 9.92 美元。</p>
<p>Adherex Technologies（納斯達克代碼：FENC - 獲取免費報告）最近一次發佈財報是在 11 月 13 日星期四。公司報告本季度每股收益（EPS）為-0.02 美元，超出市場共識預期的-0.08 美元，超出幅度為 0.06 美元。該季度的收入為 1246 萬美元，而分析師預期為 1343 萬美元。研究分析師預計 Adherex Technologies Inc.在當前財政年度將發佈-0.11 的每股收益。</p>
<h2>對 Adherex Technologies 的對沖基金看法</h2>
<p>一家機構投資者最近在 Adherex Technologies 股票中建立了新頭寸。根據其最近向證券交易委員會提交的文件，Jane Street Group LLC 在第一季度購買了 Adherex Technologies Inc.（納斯達克代碼：FENC - 免費報告）的新股份。該基金購買了 14,718 股公司的股票，價值約 90,000 美元。Jane Street Group LLC 在最近的報告期末持有 Adherex Technologies 約 0.05% 的股份。55.51% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師升級和降級</h2>
<p>幾位股票分析師對 FENC 股票發佈了報告。Weiss Ratings 在 1 月 22 日星期四的研究報告中重申了對 Adherex Technologies 股票的 “賣出（d-）” 評級。Wall Street Zen 在 1 月 17 日星期六的研究報告中將 Adherex Technologies 的股票評級從 “強買” 下調至 “買入”。Zacks Research 在 12 月 12 日星期五的報告中將 Adherex Technologies 的評級從 “強賣” 上調至 “持有”。最後，Piper Sandler 在 1 月 9 日星期五的報告中開始覆蓋 Adherex Technologies。他們給予該公司的 “增持” 評級，並設定了 18.00 美元的目標價格。四位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Adherex Technologies 目前的共識評級為 “適度買入”，共識目標價格為 14.50 美元。</p>
<p><strong>查看我們最新的 FENC 研究報告</strong></p>
<h2>關於 Adherex Technologies</h2>
<p>（獲取免費報告）</p>
<p>Fennec Pharmaceuticals Inc.是一家生物製藥公司，開發用於治療美國癌症的產品候選藥物。其主要產品候選藥物是硫代硫酸鈉，已完成用於預防順鉑引起的兒童聽力損失或耳毒性的 III 期臨牀試驗。該公司曾名為 Adherex Technologies Inc.，並於 2014 年 9 月更名為 Fennec Pharmaceuticals Inc.。Fennec Pharmaceuticals Inc.成立於 1996 年，總部位於北卡羅來納州的研究三角園。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比 Adherex Technologies 更好</li>
<li>巨大的黃金預測</li>
<li>黃金的反彈很大——但接下來可能會更大</li>
<li>美國的終結更新</li>
<li>特朗普的最後震驚行動將於 2 月 24 日開始</li>
<li>華爾街害怕的黃金圖表…</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkVOQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkVOQw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Adherex Technologies 嗎？</h2>
<p>在考慮 Adherex Technologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Adherex Technologies 並不在名單上。</p>
<p>雖然 Adherex Technologies 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

FENC

<p>Adherex Technologies Inc.（納斯達克代碼：FENC）董事 Rosty Raykov 以平均價格 7.76 美元出售了 10,349 股，總計 80,308.24 美元，持股比例減少了 9.51%。交易後，他持有 98,477 股，價值約 764,181.52 美元。該股票在午盤交易中上漲了 3.2%，至 7.83 美元。分析師對該股票的評級意見不一，普遍評級為 “適度買入”，目標價格為 14.50 美元。該公司專注於癌症治療，曾名為 Adherex Technologies，並於 2014 年更名為 Fennec Pharmaceuticals</p>

<p>Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,349 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total transaction of $80,308.24. Following the transaction, the director directly owned 98,477 shares of the company's stock, valued at $764,181.52. This represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Adherex Technologies Inc.（納斯達克代碼：FENC - 獲取免費報告）董事 Rosty Raykov 於 2 月 2 日星期一出售了 10,349 股該公司的股票。股票以平均價格 7.76 美元出售，總交易額為 80,308.24 美元。交易後，該董事直接持有 98,477 股公司的股票，價值 764,181.52 美元。這代表其持股比例下降了 9.51%。該交易已在與美國證券交易委員會（SEC）的法律文件中披露，相關信息可通過 SEC 網站獲取。</p>
</div><p>Get <strong>Adherex Technologies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Adherex Technologies</strong> 的提醒：</p>
</div><p>Rosty Raykov also recently made the following trade(s):</p>
<div class="lb-trans"><p>Rosty Raykov 最近還進行了以下交易：</p>
</div><ul>
<li>On Friday, December 5th, Rosty Raykov sold 10,000 shares of Adherex Technologies stock. The stock was sold at an average price of $7.54, for a total value of $75,400.00.</li>
<li>On Wednesday, November 5th, Rosty Raykov sold 10,000 shares of Adherex Technologies stock. The shares were sold at an average price of $8.10, for a total value of $81,000.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 5 日星期五，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均價格 7.54 美元出售，總價值為 75,400.00 美元。</li>
<li>在 11 月 5 日星期三，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均價格 8.10 美元出售，總價值為 81,000.00 美元。</li>
</ul>
</div><h2>Adherex Technologies Stock Up 3.2%</h2>
<div class="lb-trans"><h2>Adherex Technologies 股票上漲 3.2%</h2>
</div><p>Shares of NASDAQ FENC traded up $0.24 during midday trading on Monday, reaching $7.83. 134,027 shares of the stock were exchanged, compared to its average volume of 116,975. The firm has a market cap of $267.50 million, a price-to-earnings ratio of -34.04 and a beta of 0.78. The firm has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $8.28. Adherex Technologies Inc. has a twelve month low of $4.68 and a twelve month high of $9.92.</p>
<div class="lb-trans"><p>在週一的午盤交易中，納斯達克 FENC 的股票上漲了 0.24 美元，達到了 7.83 美元。該股票的交易量為 134,027 股，較其平均交易量 116,975 股有所增加。該公司的市值為 2.675 億美元，市盈率為-34.04，貝塔值為 0.78。該公司 50 日簡單移動平均線為 7.66 美元，200 日簡單移動平均線為 8.28 美元。Adherex Technologies Inc.的 12 個月低點為 4.68 美元，12 個月高點為 9.92 美元。</p>
</div><p>Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.06. The firm had revenue of $12.46 million during the quarter, compared to analyst estimates of $13.43 million. Research analysts expect that Adherex Technologies Inc. will post -0.11 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Adherex Technologies（納斯達克代碼：FENC - 獲取免費報告）最近一次發佈財報是在 11 月 13 日星期四。公司報告本季度每股收益（EPS）為-0.02 美元，超出市場共識預期的-0.08 美元，超出幅度為 0.06 美元。該季度的收入為 1246 萬美元，而分析師預期為 1343 萬美元。研究分析師預計 Adherex Technologies Inc.在當前財政年度將發佈-0.11 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Adherex Technologies</h2>
<div class="lb-trans"><h2>對 Adherex Technologies 的對沖基金看法</h2>
</div><p>An institutional investor recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 14,718 shares of the company's stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies at the end of the most recent reporting period. 55.51% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一家機構投資者最近在 Adherex Technologies 股票中建立了新頭寸。根據其最近向證券交易委員會提交的文件，Jane Street Group LLC 在第一季度購買了 Adherex Technologies Inc.（納斯達克代碼：FENC - 免費報告）的新股份。該基金購買了 14,718 股公司的股票，價值約 90,000 美元。Jane Street Group LLC 在最近的報告期末持有 Adherex Technologies 約 0.05% 的股份。55.51% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>Several equities analysts have issued reports on FENC shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Adherex Technologies from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, January 17th. Zacks Research upgraded Adherex Technologies from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, December 12th. Finally, Piper Sandler assumed coverage on Adherex Technologies in a report on Friday, January 9th. They set an &#34;overweight&#34; rating and a $18.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adherex Technologies presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $14.50.</p>
<div class="lb-trans"><p>幾位股票分析師對 FENC 股票發佈了報告。Weiss Ratings 在 1 月 22 日星期四的研究報告中重申了對 Adherex Technologies 股票的 “賣出（d-）” 評級。Wall Street Zen 在 1 月 17 日星期六的研究報告中將 Adherex Technologies 的股票評級從 “強買” 下調至 “買入”。Zacks Research 在 12 月 12 日星期五的報告中將 Adherex Technologies 的評級從 “強賣” 上調至 “持有”。最後，Piper Sandler 在 1 月 9 日星期五的報告中開始覆蓋 Adherex Technologies。他們給予該公司的 “增持” 評級，並設定了 18.00 美元的目標價格。四位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Adherex Technologies 目前的共識評級為 “適度買入”，共識目標價格為 14.50 美元。</p>
</div><p><strong>View Our Latest Research Report on FENC</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 FENC 研究報告</strong></p>
</div><h2>About Adherex Technologies</h2>
<div class="lb-trans"><h2>關於 Adherex Technologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc.是一家生物製藥公司，開發用於治療美國癌症的產品候選藥物。其主要產品候選藥物是硫代硫酸鈉，已完成用於預防順鉑引起的兒童聽力損失或耳毒性的 III 期臨牀試驗。該公司曾名為 Adherex Technologies Inc.，並於 2014 年 9 月更名為 Fennec Pharmaceuticals Inc.。Fennec Pharmaceuticals Inc.成立於 1996 年，總部位於北卡羅來納州的研究三角園。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Adherex Technologies</li>
<li>HUGE gold prediction</li>
<li>Gold’s rally is big — but what comes next could be bigger</li>
<li>End of America Update</li>
<li>Trump’s Final Shocking Act Begins February 24</li>
<li>The gold chart Wall Street is terrified of…</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Adherex Technologies 更好</li>
<li>巨大的黃金預測</li>
<li>黃金的反彈很大——但接下來可能會更大</li>
<li>美國的終結更新</li>
<li>特朗普的最後震驚行動將於 2 月 24 日開始</li>
<li>華爾街害怕的黃金圖表…</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkVOQw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=FENC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adherex Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Adherex Technologies 嗎？</h2>
</div><p>Before you consider Adherex Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Adherex Technologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adherex Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Adherex Technologies 並不在名單上。</p>
</div><p>While Adherex Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adherex Technologies 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內部人士出售：Adherex Technologies（NASDAQ:FENC）的一位董事出售了 10,349 股股票